Pleural mesothelioma
diseaseOn this page
Also known as benign pleural mesotheliomamesothelioma of pleuramesothelioma of the pleurapleura mesotheliomapleural mesothelioma (disease)pleural mesothelioma (disease), benign
Summary
Pleural mesothelioma (MONDO:0003308) is a disease and 46 clinical trials. Top therapeutic interventions include sodium thiosulfate, ipilimumab, and durvalumab. A subtype of mesothelioma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 46
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | pleural mesothelioma |
| Mondo ID | MONDO:0003308 |
| EFO | EFO:1000485 |
| DOID | DOID:5157 |
| ICD-10-CM | C45.0 |
| NCIT | C9351 |
| SNOMED CT | 109372009 |
| UMLS | C1377913 |
| MedGen | 237179 |
| Anatomy (UBERON) | UBERON:0000977 |
| Is cancer (heuristic) | no |
Also known as: benign pleural mesothelioma · mesothelioma of pleura · mesothelioma of the pleura · pleura mesothelioma · pleural mesothelioma · pleural mesothelioma (disease) · pleural mesothelioma (disease), benign
Data availability: 1 HPO phenotype · 273 cell lines · 39 intOGen driver records.
Disease family
This is a subtype of mesothelioma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › mesothelial neoplasm › mesothelioma › pleural mesothelioma
Related subtypes (6): benign mesothelioma, well differentiated papillary mesothelioma, adenomatoid tumor, malignant mesothelioma, peritoneal mesothelioma, well-differentiated papillary mesothelial tumour of the pleura
Subtypes (2): malignant pleural mesothelioma, pleural adenomatoid tumor
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 46.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 18 |
| Not specified | 12 |
| PHASE1 | 9 |
| PHASE1/PHASE2 | 5 |
| PHASE4 | 1 |
| PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05077111 | PHASE4 | UNKNOWN | A Comparative Study Between Regional Anesthesia in Thoracoscopes and the Conventional General Anesthesia |
| NCT04334759 | PHASE3 | COMPLETED | DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma |
| NCT05086692 | PHASE1/PHASE2 | RECRUITING | A Beta-only IL-2 ImmunoTherapY Study |
| NCT05930665 | PHASE2 | RECRUITING | Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma |
| NCT06155279 | PHASE2 | ACTIVE_NOT_RECRUITING | Induction Chemo+Immunotherapy in Resectable Epithelioid and Biphasic Pleural Mesothelioma (CHIMERA Study) |
| NCT06362369 | PHASE1/PHASE2 | RECRUITING | A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy |
| NCT06416930 | PHASE2 | NOT_YET_RECRUITING | Study of Cadonilimab Combined With Chemotherapy in Recurrent / Refractory Pleural Mesothelioma |
| NCT06790082 | PHASE2 | RECRUITING | The Diagnostic Accuracy and Clinical Value of FAPI PET in Pleural Mesothelioma |
| NCT06840834 | PHASE2 | RECRUITING | Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and Chemotherapy |
| NCT07234058 | PHASE2 | NOT_YET_RECRUITING | Trial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus Chemotherapy in Patients With Pleural Mesothelioma |
| NCT00165503 | PHASE2 | TERMINATED | Pleurectomy/Decortication With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Sodium Thiosulfate |
| NCT00165516 | PHASE2 | COMPLETED | Extrapleural Pneumonectomy With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Amifostine and Sodium Thiosulfate |
| NCT00859495 | PHASE2 | TERMINATED | Trimodal Lung-Sparing Treatment of Pleural Mesothelioma |
| NCT00895648 | PHASE2 | TERMINATED | Pemetrexed (ALIMTA) Plus Cisplatin Followed by Surgery and Radiation Therapy for Mesothelioma |
| NCT01160458 | PHASE2 | COMPLETED | Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy |
| NCT01861301 | PHASE2 | TERMINATED | Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma |
| NCT02414945 | PHASE1/PHASE2 | COMPLETED | TILs & Low-Dose IL-2 Therapy Following Cyclophosphamide and Fludarabine in Pleural Mesothelioma Patients |
| NCT02568449 | PHASE2 | COMPLETED | Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent |
| NCT02588131 | PHASE2 | UNKNOWN | A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1) |
| NCT02899195 | PHASE2 | COMPLETED | Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma |
| NCT04115111 | PHASE2 | COMPLETED | Diadem to Investigate the Activity and Safety of Durvalumab |
| NCT04914897 | PHASE2 | TERMINATED | A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202) |
| NCT05337735 | PHASE2 | SUSPENDED | A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers |
| NCT05598268 | PHASE1/PHASE2 | UNKNOWN | A Study of T3011 Administered Via Intravenously in Patients With Advanced Solid Tumors. |
| NCT05714553 | PHASE1/PHASE2 | TERMINATED | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours |
| NCT06726564 | PHASE1 | RECRUITING | A Study of MT027 in Patients with Pleural Malignant Tumors |
| NCT07277413 | PHASE1 | RECRUITING | A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors |
| NCT00037817 | PHASE1 | COMPLETED | Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion With or Without Concurrent Celecoxib in Subjects With Pulmonary and Pleural Malignancies |
| NCT00165555 | PHASE1 | COMPLETED | Pleurectomy/Decortication Followed by Intrathoracic/Intraperitoneal Heated Cisplatin for Malignant Pleural Mesothelioma |
| NCT00299962 | PHASE1 | COMPLETED | Gene Therapy for Pleural Malignancies |
| NCT02707666 | PHASE1 | TERMINATED | A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma |
| NCT04040231 | PHASE1 | COMPLETED | Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma |
| NCT04042480 | PHASE1 | TERMINATED | A Study of SGN-CD228A in Advanced Solid Tumors |
| NCT04430842 | PHASE1 | COMPLETED | Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S |
| NCT05538806 | Not specified | RECRUITING | TTFields in General Routine Clinical Care in Patients With Pleural Mesothelioma Study |
| NCT05628376 | Not specified | RECRUITING | TRAcking Thoracic Cancer Evolution Through Therapy (Rx) EVO |
| NCT06410625 | Not specified | RECRUITING | Evaluation of Response by FLT PET in Mesothelioma |
| NCT06971848 | Not specified | NOT_YET_RECRUITING | Evaluation of Skin Tests in Biotherapy Allergies |
| NCT07403630 | Not specified | RECRUITING | INTEGRATIVE MULTI-OMICS AND FUNCTIONAL PLATFORM FOR THE COMPLETE DIAGNOSTIC CHARACTERIZATION OF TUMORS: THE ITALIAN TUMOR CHEMOGENOMIC PROFILER (IT-TCP) |
| NCT02585362 | Not specified | COMPLETED | Whey Protein Supplement in Combination With Physical Exercise and Nutrition Program |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| SODIUM THIOSULFATE | 4 | 3 |
| IPILIMUMAB | 4 | 2 |
| DURVALUMAB | 4 | 1 |
| NINTEDANIB | 4 | 1 |
| ROMIDEPSIN | 4 | 1 |
| CADONILIMAB | 3 | 1 |
| FIANLIMAB | 3 | 1 |
| GALINPEPIMUT-S | 3 | 1 |
| INTERFERON BETA | 3 | 1 |
| IVONESCIMAB | 3 | 1 |
| TIVANTINIB | 3 | 1 |
| ALINTEGIMOD | 2 | 1 |
| CIXUTUMUMAB | 2 | 1 |
| FOSIFLOXURIDINE NAFALBENAMIDE | 2 | 1 |
| PEGENZILEUKIN | 2 | 1 |
| VUDALIMAB | 2 | 1 |
| CHEMBL3753202 | 0 | 3 |
| CHEMBL4475379 | 0 | 1 |
| CHEMBL4785734 | 0 | 1 |